Advances in engineering local drug delivery systems for cancer immunotherapy

Published on Sep 1, 2020in Wiley Interdisciplinary Reviews-nanomedicine and Nanobiotechnology9.182
路 DOI :10.1002/WNAN.1632
Peter Abdou6
Estimated H-index: 6
(UCLA: University of California, Los Angeles),
Zejun Wang17
Estimated H-index: 17
(UCLA: University of California, Los Angeles)
+ 4 AuthorsZhen Gu82
Estimated H-index: 82
(UCLA: University of California, Los Angeles)
Cancer immunotherapy aims to leverage the immune system to suppress the growth of tumors and to inhibit metastasis. The recent promising clinical outcomes associated with cancer immunotherapy have prompted research and development efforts towards enhancing the efficacy of immune checkpoint blockade, cancer vaccines, cytokine therapy, and adoptive T cell therapy. Advancements in biomaterials, nanomedicine, and micro-/nano-technology have facilitated the development of enhanced local delivery systems for cancer immunotherapy, which can enhance treatment efficacy while minimizing toxicity. Furthermore, locally administered cancer therapies that combine immunotherapy with chemotherapy, radiotherapy, or phototherapy have the potential to achieve synergistic antitumor effects. Herein, the latest studies on local delivery systems for cancer immunotherapy are surveyed, with an emphasis on the therapeutic benefits associated with the design of biomaterials and nanomedicines. This article is categorized under: Nanotechnology Approaches to Biology > Nanoscale Systems in Biology Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease.
馃摉 Papers frequently viewed together
5 Authors (Chao Wang, ..., Zhen Gu)
#1Guojun Chen (UC: University of California)H-Index: 34
#2Zhitong Chen (UCLA: University of California, Los Angeles)H-Index: 15
Last. Zhen Gu (UC: University of California)H-Index: 82
view all 9 authors...
Despite the promise of immune checkpoint blockade (ICB) therapy against cancer, challenges associated with low objective response rates and severe systemic side effects still remain and limit its clinical applications. Here, we described a cold atmospheric plasma (CAP)-mediated ICB therapy integrated with microneedles (MN) for the transdermal delivery of ICB. We found that a hollow-structured MN (hMN) patch facilitates the transportation of CAP through the skin, causing tumor cell death. The rel...
#1Jesse M. Jaynes (Tuskegee University)H-Index: 18
#2Rushikesh SableH-Index: 8
Last. Anju Singh (NIH: National Institutes of Health)H-Index: 10
view all 43 authors...
Solid tumors elicit a detectable immune response including the infiltration of tumor-associated macrophages (TAMs). Unfortunately, this immune response is co-opted into contributing toward tumor growth instead of preventing its progression. We seek to reestablish an antitumor immune response by selectively targeting surface receptors and endogenous signaling processes of the macrophage subtypes driving cancer progression. RP-182 is a synthetic 10-mer amphipathic analog of host defense peptides t...
#1Shinsuke Nakao (Astellas Pharma)H-Index: 1
#2Yukinori Arai (Astellas Pharma)H-Index: 8
Last. Takafumi Nakamura (Tottori University)H-Index: 28
view all 12 authors...
The immune status of the tumor microenvironment is a key indicator in determining the antitumor effectiveness of immunotherapies. Data support the role of activation and expansion of tumor-infiltrating lymphocytes (TILs) in increasing the benefit of immunotherapies in patients with solid tumors. We found that intratumoral injection of a tumor-selective oncolytic vaccinia virus encoding interleukin-7 (IL-7) and IL-12 into tumor-bearing immunocompetent mice activated the inflammatory immune status...
Macrophages are often the most abundant immune cell found in the tumor microenvironment, but are frequently associated with poor patient prognosis and considered detrimental to mounting an effectiv...
#1Qian Chen (Soochow University (Taiwan))H-Index: 74
#2Muchao Chen (Soochow University (Taiwan))H-Index: 11
Last. Zhuang Liu (Soochow University (Taiwan))H-Index: 152
view all 3 authors...
Cancer immunotherapy by educating or stimulating patients鈥 own immune systems to attack cancer cells has demonstrated promising therapeutic responses in the clinic. However, although the number of approved immunotherapeutics is rapidly increasing, key challenges such as limited clinical response rate and significant autoimmunity-related adverse effects remain to be resolved. Recently, it has been discovered that a diverse range of biomaterials-assisted local treatment methods including localized...
#1Di Wen (UNC: University of North Carolina at Chapel Hill)H-Index: 19
#2Jinqiang Wang (UNC: University of North Carolina at Chapel Hill)H-Index: 34
Last. Zhen Gu (UNC: University of North Carolina at Chapel Hill)H-Index: 82
view all 17 authors...
Summary Tumor-associated adipocytes promote tumor growth by providing energy and causing chronic inflammation. Here, we have exploited the lipid metabolism to engineer adipocytes that serve as a depot to deliver cancer therapeutics at the tumor site. Rumenic acid (RA), as an anticancer fatty acid, and a doxorubicin prodrug (pDox) with a reactive oxygen species (ROS)-cleavable linker, are encapsulated in adipocytes to deliver therapeutics in a tumor-specific bioresponsive manner. After intratumor...
#1Shuangqian Yan (NUS: National University of Singapore)H-Index: 12
#2Xuemei Zeng (HUST: Huazhong University of Science and Technology)H-Index: 7
Last. Xiaogang Liu (NUS: National University of Singapore)H-Index: 100
view all 6 authors...
: Synergistic phototherapy has the potential to conquer the extreme heterogeneity and complexity of difficult tumors and result in better cancer treatment outcomes than monomodal photodynamic therapy (PDT) or photothermal therapy (PTT). However, the previous approaches to combining PDT and PTT are mainly focused on primary tumor obliteration while neglecting tumor metastasis, which is responsible for about 90% of cancer deaths. It is shown that a combined PDT/PTT approach, based on upconversion-...
#1Tala ShekarianH-Index: 6
#2Eva Sivado (UCBL: Claude Bernard University Lyon 1)H-Index: 1
Last. Aur茅lien MarabelleH-Index: 66
view all 13 authors...
Although immune checkpoint鈥搕argeted therapies are currently revolutionizing cancer care, only a minority of patients develop durable objective responses to anti鈥揚D-1, PD-L1, and CTLA-4 therapy. Therefore, new therapeutic interventions are needed to increase the immunogenicity of tumors and overcome the resistance to these immunotherapies. Oncolytic properties of common viruses can be exploited for the priming of antitumor immunity, and such oncolytic viruses are currently in active clinical deve...
#1Xiao Xu (CPU: China Pharmaceutical University)H-Index: 6
#2Teng Li (CPU: China Pharmaceutical University)H-Index: 6
Last. Ran Mo (CPU: China Pharmaceutical University)H-Index: 29
view all 7 authors...
Cancer immunotherapy aims to utilize the host immune system to kill cancer cells. Recent representative immunotherapies include T-cell transfer therapies, such as chimeric antigen receptor T cell therapy, antibody-based immunomodulator therapies, such as immune checkpoint blockade therapy, and cytokine therapies. Recently developed therapies leveraging engineered cells for immunotherapy against cancers have been reported to enhance antitumor efficacy while reducing side effects. Such therapies r...
#1Chao Wang (UCSD: University of California, San Diego)H-Index: 22
#2Veronique Beiss (UCSD: University of California, San Diego)H-Index: 11
Last. Nicole F. SteinmetzH-Index: 61
view all 3 authors...
: Cowpea mosaic virus (CPMV) is a plant virus that has been developed for multiple biomedical and nanotechnology applications, including immunotherapy. Two key platforms are available: virus nanoparticles (VNPs) based on the complete CMPV virion, including the genomic RNA, and virus-like nanoparticles (VLPs) based on the empty CPMV (eCPMV) virion. It is unclear whether these platforms differ in terms of immunotherapeutic potential. We therefore compared their physicochemical properties and immun...
Cited By13
#1Peisen Zhang (CAS: Chinese Academy of Sciences)H-Index: 8
#2Yingying Li (CAS: Chinese Academy of Sciences)H-Index: 15
Last. Kevin J. McHugh (Rice University)H-Index: 16
view all 6 authors...
Abstract null null Recent advances in the synthesis of nanomaterials with diagnostic and therapeutic capabilities have been rapidly reshaping the landscape of precision medicine. Impressive progress has been made toward the design and production of innovative theranostic nanomaterials to treat a variety of diseases, yet their potential is currently limited by low bioavailability, biocompatibility, or undesirable pharmacokinetics, hindering their widespread clinical implementation. Here, we summa...
#1Runqi Zhu (CAS: Chinese Academy of Sciences)H-Index: 1
#2Tianqun Lang (CAS: Chinese Academy of Sciences)H-Index: 9
Last. Yaping Li (CAS: Chinese Academy of Sciences)H-Index: 74
view all 4 authors...
Abstract null null Immune checkpoint blockade (ICB) with immune checkpoint inhibitors (ICIs) which includes monoclonal antibodies, peptides, nucleotides, and small molecules has become one of the most promising types of cancer immunotherapy. However, insufficient efficacy and significant side effects of ICB present challenges for the further clinical application of ICB. Encouragingly, systematic and local drug delivery systems for ICIs based on nanotechnology have shown promising prospects of ad...
#1Qijuan Yuan (SYSU: Sun Yat-sen University)H-Index: 15
#2Li Wang (SYSU: Sun Yat-sen University)H-Index: 77
Last. Jun Wu (SYSU: Sun Yat-sen University)H-Index: 29
view all 5 authors...
Amino acid-based poly(ester amide) (PEA) has been utilized for various biomedical applications due to its tunable mechanical properties, good biocompatibility, and biodegradability. However, bioactive components have rarely been incorporated into the PEA structure, and there has been no systematic investigation of amino acid-based PEAs with branched structures. Herein, an in vivo metabolizable branched poly(ester amide) (BPEA) was synthesized from inositol (a natural growth factor) and amino aci...
In the past two decades, antibody-drug conjugates have gained increasing attention because they expand the therapeutic index when compared with that of traditional chemotherapies. Antibody-drug conjugates are highly complex structures consisting of antibodies covalently conjugated with small-molecule cytotoxic drugs. The complex structure of antibody-drug conjugates makes chemistry, manufacturing, and control difficult. In contrast to antibody production, distinct purification methods following ...
The increased research activity aiming at improved delivery of pharmaceutical molecules indicates the expansion of the field. An efficient therapeutic delivery approach is based on the optimal choice of drug-carrying vehicle, successful targeting, and payload release enabling the site-specific accumulation of the therapeutic molecules. However, designing the formulation endowed with the targeting properties in vitro does not guarantee its selective delivery in vivo. The various biological barrie...
Introduction: We discuss chemical conjugation strategies for antibody-drug conjugates (ADCs) from an industrial perspective and compare three promising chemical conjugation technologies to produce ...
#1Michael A Luzuriaga (Harvard University)H-Index: 9
#2Arezoo Shahrivarkevishahi (UTD: University of Texas at Dallas)H-Index: 5
Last. Jeremiah J. Gassensmith (UTD: University of Texas at Dallas)H-Index: 25
view all 5 authors...
Vaccines are considered one of the most significant medical advancements in human history, as they have prevented hundreds of millions of deaths since their discovery; however, modern travel permits disease spread at unprecedented rates, and vaccine shortcomings like thermal sensitivity and required booster shots have been made evident by the COVID-19 pandemic. Approaches to overcoming these issues appear promising via the integration of vaccine technology with biomaterials, which offer sustaine...
#1Mahesh P. MoreH-Index: 10
#2Sagar R. Pardeshi (North Maharashtra University)H-Index: 5
Last. Abhijeet D. kulkarniH-Index: 2
view all 8 authors...
Abstract The graph of drug resistance in cancer is reportedly increasing in terms of therapeutic efficiency. As per the WHO reports, around 70% of death reported in low- and middle-income countries. The increase in death toll was imparted from improper diagnosis and inadequate therapy. The 25% increase in disease burden may be laden due to resistance mutations in cancer during treatment. Exposure of high concentrations of chemotherapeutic agents leads to toxicity in the normal cells. Long-term c...
#1Preethi B. Balakrishnan (GW: George Washington University)H-Index: 8
#2Elizabeth E. Sweeney (GW: George Washington University)H-Index: 10
Adoptive T cell therapy has emerged as a revolutionary immunotherapy for treating cancer. Despite immense promise and clinical success in some hematologic malignancies, limitations remain that thwart its efficacy in solid tumors. Particularly in tumors of the central nervous system (CNS), T cell therapy is often restricted by the difficulty in intratumoral delivery across anatomical niches, suboptimal T cell specificity or activation, and intratumoral T cell dysfunction due to immunosuppressive ...
#1Xinyi Lin (Xi'an Jiaotong University)H-Index: 9
#2Xiaoyan Wang (Fujian Agriculture and Forestry University)H-Index: 3
Last. Cuiping Yao (Xi'an Jiaotong University)H-Index: 16
view all 6 authors...
Immunotherapy was emerged as a novel cancer treatment in the last decade, however, efficacious responses to mono-immunotherapy have only been achieved in a relatively small portion of patients whereas combinational immunotherapies often lead to concurrent side effects. It has been proved that the tumor microenvironment (TME) is responsible for tumor immune escape and the ultimate treatment failure. Recently, both the understanding of the TME and the applications of nanotechnological strategies h...
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.